Antibody drug conjugate: Recent Episodes
Bella Smith
What is an ADC? Three major components define an ADC—the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. A successful ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized. https://www.creative-biolabs.com/adc/services.htm
All chemical linkers are of >95% purity and they are the basic building blocks for a successful ADC. Linkers facilitate the conjugation of ADC toxins to antibodies and in the meantime, they also dictate the release mechanism of an ADC. Proper linker selection will not only ease the process of obtaining the conjugate but also help enhance the chemical and serum stability of the ADC, such as val cit pab. https://www.creative-biolabs.com/adc/classify-adc-linkers-7.htm
ADC toxins target crucial intracellular pathways to induce cell death and they can be over 1000-fold more potent than chemo therapeutic agents. A large selection of ADC toxins range from common auristatins, maytansinoids, calicheamicins to more innovative toxins such as amatoxins, polyketomycin…. https://www.creative-biolabs.com/adc/classify-adc-toxins-6.htm
Ipatasertib shows a powerful inhibition of all protein kinase B (Akt) isoforms but a weak suppression towards other members of the protein kinase family. Treatments of both tumor xenograft mouse models and human cancer cell lines with ipatasertib showed a significant suppression of Akt signaling, leading to a disruption in cell cycle progression and reduced cancer cell viability. https://www.creative-biolabs.com/adc/ipatasertib-akt-inhibitor.htm
Multiple endogenous amino acids can serve as potential conjugation sites. However, to achieve more precisely controlled site-directed conjugations and subsequently a narrower distribution of drug-to-antibody ratio (DAR), special moieties with unique conjugation chemistries are engineered into antibody sequences in antibody design services. One downside in using the endogenous amino acids for ADC development is a heavily dispersed DAR conjugation caused by the non-uniform distribution of the conjugation sites, especially in the case of Lysine-based conjugations. https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
ADEPT antibody is regarded as an “indirect targeting method” that involves two steps. Firstly, a non-toxic antibody–enzyme fusion protein is applied to the tumor matrix and binds to the tumor cells via tumor-specific antigen recognized by the antibody. Upon binding, an inert small-molecule prodrug is then given. The prodrug is the substrate for the enzyme portion of the antibody–enzyme fusion that is anchored to the tumor surface. Once the prodrug reaches the enzyme, an active cytotoxic agent is produced by the enzyme and cause cancer cell death. https://www.creative-biolabs.com/adc/toxic-enzymes-adept.htm
The target-oriented high-quality ADC custom products are suitable for tasks such as proof-of-concept, target validation, as well as control to provide comparison in efficacy for new ADC development projects. https://www.creative-biolabs.com/adc/target-list-customized-adcs-1.htm
As the new generation of immunotherapy, ADCs are meticulously constituted bio-macromolecules with high potential in the treatment of cancer and various other diseases. The information gathered from in vitro analysis provides a guideline for ADC optimization and the downstream in vivo ADC assessment. https://www.creative-biolabs.com/adc/adc-in-vitro-analysis.htm
To retain antibody bioactivity, mild, near-physiological conditions are often used for conjugation reactions. Under these conditions, endogenous amino acids such as Lys and Cys are chemically reactive and can be used as conjugation sites. One downside in using the endogenous amino acids for ADC development is a heavily dispersed conjugation of DAR caused by the non-uniform distribution of the conjugation sites, especially in the case of Lysine-based conjugations. https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
During the development of effective and safe antibody-drug conjugates some technical issues arose. The generation of an appropriate chemical linkers between the monoclonal antibody and the cytotoxic drug turns out to be a major difficulty. This is due to the complex synthesis of linker chemistry. On the other hand, the design of types of linkers is highly dependent on the target cells biology, the antibody characteristics, and the molecule structure of the drug. With the development of ADCs introduced to clinical trials or approved by the FDA, a series of typical linkers are now in use. https://www.creative-biolabs.com/adc/linker-module.htm
A suitable payload drug will be selected and coupled with a linker with desired releasing mechanism in “DrugLnk” to assemble the “chemical warhead” for an ADC, which is subsequently conjugated with the desired antibody using Antibody Design and Conjugation services. Certain modification or engineering of the selected antibody is also carried out in antibody conjugation service module. https://www.creative-biolabs.com/adc/antibody-drug-conjugate-adc.htm
As one major component of antibody conjugates, the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload drug can be attached to different sites on an antibody using diverse conjugation chemistry. https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
Antibody-drug conjugates (ADCs) inherit high specificity and affinity towards well-defined targets and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature. Therefore, ADCs have raised great attention in antibody chemistry filed. https://www.creative-biolabs.com/adc/antibody-drug-conjugate-adc.htm
Ipatasertib, also known as GDC-0068, is a strong ATP-competitive pan AKT inhibitor. It was initially derived during the screening and optimization process of a series of 6,7-dihydro-5H-cyclopenta[d]pyrimidine compounds. https://www.creative-biolabs.com/adc/ipatasertib-akt-inhibitor.htm
Compared with conventional therapeutic treatment, monoclonal immunotherapies are highly advantageous due to their high specificity and affinity towards well-defined targets and so are antibody-drug conjugates (ADCs). Moreover, consisting of the monoclonal antibody, a cytotoxic payload, and a molecular linker, ADC expands the therapeutic window of the conjugated drugs (payloads), which is usually highly toxic and diverse in their biochemical nature. https://www.creative-biolabs.com/adc/services.htm
These high-quality custom ADCs are suitable for tasks such as proof-of-concept, target validation, as well as control to provide comparison in efficacy for new ADC development projects. The ADC custom products are target-oriented. https://www.creative-biolabs.com/adc/target-list-customized-adcs-1.htm
Mass spectrometry techniques can be used to evaluate the stability of the linker, analyze free drugs, metabolites, different DAR components, and relative proportions. LC/MS, such as HIC or RP-HPLC coupled with mass spectrometry, has been used for ADC drug structure and composition analysis, to evaluate the stability of ADC linkers, to analyze DAR and coupling sites, and to determine the relative DAR components. Proportion and so on.
One of the challenges of mass spectrometry technology is that all substances have the same ionization efficiency as unconjugated antibodies, regardless of drug loading. Therefore, the premise of applying spectroscopy to the analysis of DAR conjugation is to assume that all materials have the same recovery and ionization. This is not always the case, as the coupling of the drug to the positively charged amine will result in a change in the charge and degree of hydrophobicity.
https://www.creative-biolabs.com/adc/classify-adc-linkers-7.htm
Antibody-drug conjugates (ADCs) are a class of drugs that conjugate a monoclonal antibody to a different number of small molecule cytotoxins (effector molecules) by chemical linkers. This novel drug combines the high specificity of monoclonal antibodies with the high activity of small molecule toxins.
Chromatographic analysis of antibody-conjugated drugs and their enzymatic products can obtain important information such as the number and location of coupling sites, free drug content, and drug-antibody coupling ratio. At the same time, chromatographic separation techniques can purify different components for further analysis. Chromatographic techniques based on hydrophobic, charge and molecular size principles have been widely used to analyze antibody conjugation.
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
For the conjugated antibody ELISA, when a drug-resistant antibody is used as a capture agent, it may not be possible to uniformly measure ADC drug with different drug loadings, and with anti drug conjugate as detection reagents, it may not be possible to obtain a ratio proportional to the number of drug molecules. https://www.creative-biolabs.com/adc/services.htm
Immunoassays include detection of binding of antibody-conjugated drugs to target proteins; quantitative ADC analysis; evaluation of stability of linkers and drugs; detection of binding to FcγR and evaluation of immunogenicity. These assays are important for understanding the potency, pharmacokinetics, and safety of antibody-conjugated drugs. Among them, enzyme-linked immunosorbent assays are often used to evaluate the concentration of antibody-drug conjugates and their binding to antigens.
ELISA types for antibody-drug conjugates analysis include total antibody ELISA, semi-homogeneous ELISA, competitive ELISA, and coupled antibody ELISA. The specific total antibody ELISA refers to coating a target antigen or an anti-idiotypic antibody on a well plate, and using an enzyme-specific anti-immunoglobulin secondary antibody to detect the binding of the ADC to the coated antigen. In the case of a semi-homogeneous ELISA, the capture antibody and the detection antibody form a complex with the ADC prior to immobilization to the well plate, and exhibit significant advantages in analyzing antibody-conjugated drugs of different drug loadings.
https://www.creative-biolabs.com/adc/adc-in-vitro-analysis.htm
Antibody-drug conjugates (ADCs) are a class of drugs that conjugate a monoclonal antibody to a different number of small cytotoxins (payloads) by chemical linkers, combining the high specificity of monoclonal antibodies with the high activity of small molecule toxins.
For different types of analytes, researchers need to select different analytical methods according to the different purposes of drug development and evaluation and the characteristics of the analytes, and complete the testing tasks with different standards. The important research object in physicochemical properties is the drug antibody ratio (DAR).
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
Creative Biolabs, a leading services provider who is committed to providing high-quality services to promote the development of antibody-drug conjugates (ADCs) and other innovative targeted protein therapeutic agents, recently upgraded their advanced ADC technologies covering all crucial stages in ADC development.
"It is worth mentioning our DrugLnk synthesis platform to prepare customized linkers with unique structures. This special platform helps generate a successful ADC linker of >95% purity to facilitate antibody-drug conjugate (ADC) development projects. We can provide a variety of chemically versatile linker molecules, including cleavable linkers, non-cleavable linkers, and intermediate linker modules equipped with with good blood stability and highly specialized conjugation chemistry, such as SMCC"
https://www.creative-biolabs.com/adc/classify-adc-linkers-7.htm
Ovarian malignant tumor is one of the common malignant tumors of female reproductive organs, and its incidence rate ranks third only after cervical cancer and endometrial cancer. However, the mortality of ovarian epithelial cancer accounts for the first place in all kinds of gynecological tumors, posing a serious threat to women's lives. It is therefore critical to ensure that the ADC releases the drug while it is still extracellular. To achieve this goal, Tagworks has designed a smart ADC that binds to cancer receptors when injected into the body, and after 1-2 days, the cells are enriched with ADCs. Robillard said: "Our innovation is that we use a second component that can 'click release' chemotherapy drugs from the ADC. The result is a large number of chemotherapy drugs that release quickly and attack the tumor. This method is promising for a variety of treatments. "
https://www.creative-biolabs.com/adc/services.htm
Overexpression of HER2 can also be seen in other tumors such as the ovary, endometrium, bladder, lung, colon, and head and neck. HER2 ADC targeted therapy has greatly improved the prognosis of HER2-positive breast and gastric/esophageal cancer patients; however, the efficacy of other HER2 overexpressing cancers has been disappointing.
Tom Held, the vice president and head of cancer research, said: "I am pleased to have the opportunity to work with Keytruda to assess the safety, tolerability and activity of DS-8201, and whether this combination can express advanced breast cancer for HER2 and patients with non-small cell lung cancer offer a potential new approach to ADC analysis. This strategic collaboration supports our goal of pursuing, researching and maximizing the use of DS-8201 in combination with other compounds for different pathways to address needs of cancer patients."
https://www.creative-biolabs.com/adc/target-erbb2-37.htm
DS-8201 is the first antibody-drug conjugate (ADC) under the First Sankyo Pharmaceutical Co., Ltd. ADC is a cancer-targeting drug that delivers cytotoxic chemotherapeutic drugs to cancer cells via a linker attached to a monoclonal antibody that binds to specific targets expressed on cancer cells. ADC antibody use a specific linker to link antibodies to small molecule cytotoxic drugs called ADC payload. The main components include antibodies, linkers, and small-molecule cytotoxic drugs (SM). Antibody molecules mainly play a targeted delivery role, and small molecule drugs exert an effect. However, some antibodies have anti-tumor pharmacodynamic effects, such as the synergistic effect of ado-trastuzumab and maytansine in Kadcyla.
https://www.creative-biolabs.com/adc/maytansinoids.htm
Antibody drug conjugate (ADC) is a calss of relatively invonational anticancer drugs, consisting of an tumor killing chemotherapeutic drug that targets and binds to cellular receptors. The antibodies on the ADC are mainly used to bind tumor cell-specific extracellular receptors. Through ADC delivery, the drug is released after the receptor delivers the entire structure into the cell, and then the chemotherapeutic drug acts in the cell.
https://www.creative-biolabs.com/adc/services.htm
Empowered by advanced technical platforms, scientists with Ph. D levels in Creative Biolabs devote themselves to providing their clients with comprehensive ADC services from antibody design to 3D Cell Culture.
"We have adopted a variety of strategies in antibody design and engineering to generate new monoclonal antibodies with accommodating conjugation chemistry sites for the creation of ADCs. Our team is also able to manufacture recombinant antibodies, protein conjugates, and ADCs in cGMP certified facilities. 3D Cell Culture systems are adopted to help painting a more comprehensive picture of the ADC behavior under these circumstances while properly evaluating the "bystander" killing effect of an ADC in these cell clusters", said the key scientist in Creative Biolabs.
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
Creative Biolabs, a leading services provider who is committed to providing high-quality services to promote the development of antibody-drug conjugates (ADCs) and other innovative targeted protein therapeutic agents, recently upgraded their advanced ADC Technologies covering all crucial stages in ADC development. Empowered by advanced technical platforms, scientists with Ph. D levels in Creative Biolabs devote themselves to providing their clients with comprehensive services from antibody design to 3D Cell Culture.
https://www.creative-biolabs.com/adc/platform.htm
As next-generation promising medicines with specific targeting ability in immunotherapy, antibody-drug conjugates are expected to have high potential and wide applications in treating various types of cancer, fungal or bacterial infections, cardiovascular disorders, and immune diseases.
Three major components define an ADC—the monoclonal antibody, a cytotoxic payload, and a molecular linker that covalently bridges the other two components. A successful ADC should be chemically and physiologically stable in blood stream, exert similar antigen binding pattern compared with the unconjugated antibody, and exhibit desired payload toxicological effects once internalized.
https://www.creative-biolabs.com/adc/services.htm
Antibody-drug conjugates (ADC) have emerged. There are several key points in the design of antibody-conjugated drugs: 1) suitable targets can specifically target tumor cells; 2) antibodies corresponding to them can accurately find targets; 3) cytotoxins, which have sufficient toxic effects to kill Tumor cells; 4) ADC linkers that link antibodies to cytotoxins to ensure that they do not break in the circulatory system of the body, but break within the tumor cells and release cytotoxins; 5) Link antibodies, cytotoxins and linkers together The combination of technology. The production of these three substances involves both biotechnology and chemical synthesis. Toxic payload drugs are an essential component of any therapeutic ADC. In reality, not every toxin is suitable to be used as an adc payload.
https://www.creative-biolabs.com/adc/drug-module.htm
ADC antibody occasionally induces antigen-mediated anticancer activity. Other challenges for targeting tumor antigens with ADCs include high stromal tumor pressure, physiological and kinetic energy barriers, and bystander effects.
Second-generation ADC is more stable than the first-generation connector, the toxic load is more effective, but based on the random coupling strategy, the conjugation DAR is heterogeneous, the drug stability is low, the non-specific toxicity is increased, and the half-life of the ADCs is reduced. As for the third generation of ADC, owing to site-specific antibody conjugation (sulfur bridge method, introduction of non-natural amino acids, enzymatic strategy), with homogeneous, single ADC is more effective cytotoxic carrier. There are currently four PBD-containing ADCs in Phase I and Phase II clinical trials.
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
What is an antibody drug conjugate? Antibody-drug conjugates (ADCs) bridged by smart linkers have an improved therapeutic window that efficiently targets tumor cells and tissues. ADCs comprise a high affinity antibody and a cytotoxic payload coupled by a suitable linker. The development of protein engineering, linker chemistry and new cytotoxic loads presupposes ADC to be a safe and effective anticancer therapy for personalized medicine. ADC has become a more powerful tool for targeting cancer treatment, and its "drug antibody ratio" (DAR) has also improved, and the number of clinical trials has also increased significantly.
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
Dissociation of the ADC in the blood of the tissue can result in damage to normal tissue and can affect the therapeutic effect. Therefore, the design of the drug conjugation is required to take into account the stability of the antibody drug complex and the separation and killing effect after entering the target cell.
The conjugates include both cleavable and non-cleavable. The cleavable conjugates are designed to stabilize in the blood pH environment and hydrolyze in the pH environment of the cells, thereby releasing cytotoxic drugs and killing cancer cells. However, clinical studies have shown that such ADC drugs can undergo non-specific hydrolysis in some cases to cause side effects.
Non-cleavable conjugates are often associated with degradation of ADC drugs, which are often linked to small molecules to lysine and cysteine of degradable monoclonal antibodies during degradation of ADC platform.
https://www.creative-biolabs.com/adc/platform.htm
As a valuable partner focused on antibody-drug conjugates (ADCs) research and development, Creative Biolabs recently launched a powerful ADC payload called amatoxin based on their exclusive “DrugLnk” organic synthesis platform.
Antibody-drug conjugates (ADCs) are next-generation targeted anti-tumor agents, consisting of a monoclonal antibody with a cytotoxic payload drug via a small molecular linker. The toxic payload drug as an essential component of any therapeutic ADC plays a decisive role in determining its efficacy.
“In reality, not every toxin is suitable to be used as an ADC payload. To serve this very purpose, the toxins must exert extremely high cytotoxic efficacy and adequate plasma stability with a small size to minimize the risk of immunogenicity. Since current ADC strategies rely on the internalization of the toxin conjugates, the targets of the payloads must be located inside the cell.” Said a scientist from Creative Biolabs.
https://www.creative-biolabs.com/adc/amatoxins.htm
“To retain antibody bioactivity, mild, near-physiological conditions are often used for conjugation reactions. Under these conditions, endogenous amino acids such as Lys and Cys are chemically reactive and can be used as conjugation sites. We made a great effort to complete this complicated and difficult task by engineering special moieties with unique dar conjugation chemistries into antibody sequences in our antibody design services.” A scientist from Creative Biolabs said that.
“Alongside the efforts of antibody engineering, we also apply several enzymatic or physical approaches to afford site-specific anti drug conjugate by modifying the carbohydrate moiety via galactosidases and galactosyltransferases or photo-crosslinking indole-3-butyric acid containing linkers onto antibody nucleotide binding site.”
https://www.creative-biolabs.com/adc/antibody-design-and-conjugation.htm
As a biopharmaceutical company highly specialized in advanced antibody biochemistry and engineering, Creative Biolabs recently has launched a comprehensive antibody design and conjugation service, intending to become the best companion of global clients in custom ADC field.
What is ADC? Antibody drug conjugate (ADC), generally refers to a monocule compound consisting of a desirable monoclonal antibody, an active cytotoxic payload, and a suitable molecular linker, in which the antibody is the key for target specificity and serves as the cargo to deliver the cytotoxic drug (payload). A payload can be attached to different sites on an antibody in the use of diverse conjugation chemistry.
https://www.creative-biolabs.com/adc/drug-module.htm
Antibody-drug conjugates selectively and continuously deliver cytotoxic drugs to tumors. Its three main components are antibodies, cytotoxic agents and linkers. Many monoclonal antibodies are standard therapies for solid tumors and hematological cancers, while primary chemotherapy drugs have limited therapeutic effects on cancer due to their non-specific toxicity. The discovery of ADC fills the gap between the two. Mylotarg is the first FDA approved ADC for acute myeloid leukemia. Adcetris is a conjugate of the CD30 antibody and monomethyl auristatin E and is approved for the treatment of lymphoma. Kadcyla has been commercialized for HER-2 positive metastatic breast cancer. The challenges faced by ADCs include antibody immunogenicity, antigen expression, premature drug release, etc. Progress in bioengineering has improved its safety and efficacy.
https://www.creative-biolabs.com/adc/services.htm